The acquisition of a Global Data Publications web subscription bundle for a milestone tracking database for NCI SBIR/STTR programs.

1.0 DESCRIPTION The Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI), Small Business Innovation Research (SBIR), plans to procure, on a sole source basis, a database subscription to support a Congressional reporting mandate from Global Data Publications Inc., 441 Lexington Avenue, 3rd Floor, New York, NY. The response close date of the notice for this requirement is in accordance with FAR 5.203(b). This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR Part 13.106-1(b)(1)(i); and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 519290 and the small business size standard is 1,000 employees. It has been determined there are no opportunities to acquire green products or services for this procurement. 2.0 BACKGROUND The U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI), Small Business Innovation Research (SBIR), requires a database subscription to support a Congressional reporting mandate. In 2017, in response to the increasing demand for agency SBIR/ Small Business Technology Transfer (STTR) to evaluate their program, the SBIR Development Center procured a subscription from Global Data Publications to access the Pharma Intelligence and Medical Intelligence Centre databases. The data retrieved from this subscription directly supports a reporting requirement for a Congressional Mandate. As part of the SBIR/STTR Congressional mandate, the National Academy of Science (NAS) completes a study and report on the SBIR or STTR programs using information provided by SBIR which has been retrieved from the referenced database subscription. The reports generated by the NAS are specifically intended to inform Congress on the activities of the SBIR/STTR programs at various agencies, as well as make recommendations for improvement. In support of this ongoing reporting requirement to continue collecting metrics data on NCI SBIR awardees, NCI SBIR requires a database resource. 3.0 SCOPE This acquisition includes a twelve (12) month web subscription bundle to Global Data Publications for four (4) individual categories of subscriptions as noted in section 3.1. The Global Data subscription bundle shall provide research solutions covering the full breadth of the pharmaceuticals industry, from clinical trials and epidemiology intelligence, to focused modules available across multiple therapy areas. 3.1 REQUIRED ITEMS The following items are required: Item Description: Global Data Web Subscription Bundle, Quantity: 1 -Bundle includes the following: 1) Global Data Web Subscription - 5 Users, Pharma -Intelligence Centre-Trials Intelligence; 2) Global Data Web Subscription - 5 Users, Pharma Intelligence Centre-Therapeutic Analysis; 3) Global Data Web Subscription - 5 Users, Pharma Intelligence Centre- Drug Intelligence; 4) Global Data Web Subscription - 5 Users, Medical Intelligence Centre-License 4.0 SPECIAL ORDER REQUIREMENTS 4.1 PRODUCT FEATURES/SALIENT CHARACTERISTICS The required subscriptions shall enable access to the underlying database and support the following product features/characteristics: Includes a comprehensive source of data on all types of oncology technologies and companies. The NCI SBIR/STTR development center funds a diverse portfolio of small businesses across various technology areas, such as therapeutics, in vitro diagnostics, medical devices, health IT and research tools. Thus, the milestone tracking tool needs to have such coverage. Can track all types of business milestones including but not limited to capital raisings, partnerships, and licensing agreements. Although SBIR funding is important for small businesses at early stage, it is insufficient to translate the technology from discovery to commercial product. Early-stage small businesses must connect to follow-on capital and resources to bring NCI SBIR-funded technologies to patients. Thus, follow-on business milestones are important metrics for the NCI SBIR development center to collect. Can provide detailed data (e.g., technology area of focus, ideal technology stage) on life science investors and strategic partners. Since follow-on capital and resources are so vital for small businesses to bring NCI SBIR-funded technologies to patients, the NCI SBIR development center has special programs and network opportunities to incentivize collaborations between NCI SBIR-funded companies and investors/partners. To continue building and expanding an active investor/partner network, the NCI SBIR development center requires a data source to find active investors and strategic partners and keep track of their specific investment focus, deal size, ideal technology stage for investment, and other factors. Can track all types of scientific milestones of NCI SBIR-funded technologies including but not limited to clinical trials, regulatory filings, publications, and patents. In addition to business milestones, scientific milestones are also important metrics for the NCI SBIR development center to collect. By collecting these metrics, the NCI SBIR-funded technologies can follow SBIR-funded technologies across the R&D lifecycle from discovery and clinical development through regulatory submission and commercialization. Ability to identify NCI SBIR-funded technologies and link them with NCI SBIR/STTR fundings. It is common that a company leaves NCI SBIR/STTR program when it is still at an early stage and the final report cannot clearly tell what product has resulted from SBIR investments. Thus, this ability is vital for the NCI SBIR development center to avoid tremendous manual work to determine all NCI SBIR-funded technologies. Provide detailed categorization of NCI SBIR-funded technologies including but not limited to cancer indication, development stage, technology type and target. The NCI SBIR development center requires these data for different purposes such as keeping investor/partner network abreast of the program, federal reporting, and regular program evaluation. 4.1 DELIVERY/INSTALLATION The contractor shall provide access to the database within one (1) business day of award. 5.0 UNIQUE QUALIFICATIONS OF THE CONTRACTOR The Government requires access via a subscription bundle to a specialized, proprietary database that has been utilized since 2017. Global Data is the sole provider of the required subscription bundle. The database provided by Global Data was specially designed for tracking all types of biotechnology companies milestones across the biotechnology Research & Development lifecycle from discovery and clinical development through regulatory submission and commercialization. Global Data is the only vendor capable of providing a database that incorporates data tracking with biomedical technology development milestones that are appropriate for post-award metrics collection. In addition, Global Data is the only vendor capable of providing access to a database that meets 100% of the Government's requirements in a single place. Specialized features supporting the unique functionality of the database are as follows: Provide data on all types of oncology technologies and companies; Track business milestones (e.g., capital raising, M&A, partnership, licensing); Track scientific milestones (e.g., clinical trial, regulatory filing, publication, patents); Identify NCI SBIR-funded technologies and link them back to NCI SBIR funding; Track commercial milestones (e.g., commercial product, sales, use rates/market penetrance); Provide detailed data (e.g., technology area of focus, ideal technology stage for investment) on life science investors and strategic partners; Have detailed categorization and information identifying-funded technologies including but not limited to cancer indication, development stage, technology type and target; Allow users to set custom trackers; and Send automated reminders. Given the unique objectives of the NCI SBIR program, the detailed product information and funding source data is critical to meet the government's needs. 6.0 SUBMISSION INSTRUCTIONS This notice is not a request for competitive quotations. However, if any interested party believes it can meet the above requirements, it may submit a proposal or quote for the Government to consider. The response and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. All responses and questions must be sent via email to the Contract Specialist, Holly Knott, at holly.knott@nih.gov by no later than 10:00 AM EST on December 29, 2022. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, Contractors must be registered and have valid certification through SAM.gov. Reference: 75N91023Q00016 on all correspondence.